NCT05404542View on ClinicalTrials.gov

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions
Renal Impairment
Interventions
DRUG

Tavapadon

Oral tablets

Trial Locations (3)

32216

Jacksonville, Florida, Jacksonville

33147

Miami, Florida, Miami

33603

Tampa, Florida, Tampa

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05404542 - To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function | Biotech Hunter | Biotech Hunter